Ionis Pharmaceuticals (IONS) CEO Brett Monia Buys $475K of Stock

Ionis Pharmaceuticals, Inc. (IONS) Chief Executive Officer Brett Monia increased his position in the company on June 24, 2026. According to a filing with the SEC, Monia purchased 14,565 shares at a price of $32.60 each. This transaction was worth $474,819 and was not part of a pre-arranged trading plan.

Ionis Executive Buying Activity

This purchase by the CEO follows a series of other acquisitions by top leaders at the company. On June 26, 2026, Executive Vice President Eugene Schneider bought 26,000 shares at $60.89 each, a trade valued at $1.58 million. The same day, Chief Business Officer Joseph Baroldi added 5,635 shares to his holdings at a price of $49.19, totaling about $277,181. These buys happened around the same time Monia also reported a sale of 14,565 shares on June 24, though he remains a major stakeholder. Earlier in the month, Spencer Berthelsen sold 8,000 shares on June 15, 2026, under a Rule 10b5-1 plan at $73.49 per share.

Analysts Set New Price Targets

Wall Street firms have been busy updating their views on Ionis throughout the fall. On October 15, 2026, UBS upgraded the stock to a Buy rating and set a price target of $88.00. HC Wainwright & Co. reiterated its Buy rating on September 24, 2026, with a $100.00 price target. Earlier in September, several other firms adjusted their targets while keeping positive ratings: Morgan Stanley maintained an Overweight rating with a $104.00 target, and Barclays kept its Overweight rating with a target of $85.00. Currently, 22 analysts cover the stock with a consensus recommendation of Hold.

Stock Performance and Recent Financials

On Saturday, the stock was priced at $81.18. This is quite strong compared to its 52-week range, where it has traded as low as $44.20 and as high as $86.74. The company has shown significant growth since the CEO's June purchase. In its most recent financial updates, Ionis reported revenue of $874.09 million. While the company is not currently profitable and does not have a meaningful P/E ratio, it maintains a current ratio of 7.89, suggesting it has plenty of cash on hand to cover its short-term bills.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is a biotechnology firm based in Carlsbad, California, that specializes in RNA-targeted medicines. They develop treatments for rare diseases, including conditions that affect the nervous system and heart health. The company has several products already on the market and many others in late-stage clinical trials, often working with big partners like Biogen and AstraZeneca.

What's Ahead for Ionis Pharmaceuticals, Inc.

Investors will be watching for the next financial update from Ionis, which is expected on November 4, 2026. The recent cluster of executive buying activity often draws attention, though it is just one factor among many that can influence a stock's direction. Future filings will show if the management team continues to build their personal stakes as the company moves its newer drugs toward potential approval.